RMD
RMD
RMD
ResMed Inc has announced that it will report its first quarter fiscal 2027 earnings on October 29, 2026. The company approaches this update with a market capitalization of $33.12 billion and an annual revenue of $5.65 billion. ResMed also holds a PE ratio of 21.87, a trailing twelve-month EPS of 10.53, and a free cash flow yield of 8.72%.
Based on globenewswire.comTop 50 High-Quality Dividend Growth Stocks For October 2026
ResMed (NYSE:RMD) CEO Sells $1,129,613.03 in Stock
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
Engineers Gate Manager LP Has $1.58 Million Stake in ResMed Inc. $RMD
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Blinx with professional market data, charts beside chat, and your portfolio context.
Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.